Bli medlem
Bli medlem

Du är här

2018-01-15

Oncology Venture: Oncology Venture will execute license to multi TKI phase 3 compound

Hoersholm, Denmark, January 15th, 2018 - Oncology Venture Sweden AB
(OV:ST): As previously announced to the market on December 14, 2017
Oncology Venture hereby disclose the initial conclusion from a study
of the DRP of a phase 3 TKI product from Big Pharma: in the study of
data from renal cancer patients' biopsies - where the DRP score was
compared with the outcome of clinical trial results - a consistent
result was found. Based on this, the Company's goal is to develop the
drug and it's DRP to commercial success. Several parameters were
evaluated in this blinded study and though some were not
statistically significant, others were, and a consistent signal was
seen of the TKI DRP's ability to foresee clinical benefit in the
phase 3 TKI trial in renal cancer patients.

Oncology Venture has decided to execute the TKI license - which has
already been negotiated. No further details have been disclosed on
the financial content of the deal.

In addition to 2X Oncology, of which Oncology Venture currently owns
92%, Oncology Venture has spun out Danish OV-SPV 2, which will test
and potentially develop an in-licensed, oral phase 2 Tyrosine Kinase
inhibitor.

"The TKI product will be the strongest and most advanced in OV's
pipeline with clear efficacy in several cancers. I am confident that
we can develop the TKI to commercialisation and once we have the full
data package in-house we can further develop the DRP to a useful tool
for clinical guidance to foresee patients' benefit of the drug ",
says Peter Buhl Jensen, MD, PhD and CEO of Oncology Venture.

For further information, please contact

Ulla Hald Buhl, COO and Chief IR & Or Peter Buhl Jensen, CEOMobile:
+45 21

CommunicationsMobile: +45 2170 60 89 22E-mail:
1049uhb@oncologyventure.com pbj@oncologyventure.com
About the Drug Response Predictor (DRP®) Companion Diagnostic

Oncology Venture uses the Medical Prognosis Institute (MPI) multi gene
DRP® technology to select those patients that, by the genetic
signature in their cancer, is found to have a high likelihood of
response to a given drug. The goal is to develop the drug for the
right patients by screening patients before treatment, whereby the
response rate can be significantly increased. The DRP® method builds
on the comparison of sensitive vs. resistant human cancer cell lines
including genomic information from cell lines combined with clinical
tumor biology and clinical correlates in a systems biology network.
The DRP® is based on messenger RNA from the patients' biopsies. The
DRP® platform (i.e. the DRP® and the PRP™ biomarkers) can be used in
all cancer types, and is patented for more than 70 anti-cancer drugs
in the US. The PRP™ is commercialized by MPI for Personalized
Medicine. The DRP® is commercialized by Oncology Venture for drug
development.

About Oncology Venture Sweden AB

Oncology Venture Sweden AB is engaged in the research and development
of anti-cancer drugs via its wholly owned Danish subsidiary Oncology
Venture ApS. Oncology Venture has an exclusive license to use the
Drug Response Predictor (DRP®) technology in order to significantly
increase the probability of success in clinical trials. DRP® has
proven its ability to provide a statistically significant prediction
of clinical outcomes from drug treatment in cancer patients in 29 of
the 37 clinical studies that were examined. The Company uses a model
that alters the odds in comparison with traditional pharmaceutical
development. Instead of treating all patients with a particular type
of cancer, patients' tumors' genes are screened first with DRP® and
only those who are most likely to respond to the treatment will be
treated. Via a more well-defined patient group, the risk and costs
are reduced while the development process becomes more efficient.

The current product portfolio: LiPlaCis® for Breast Cancer in
collaboration with Cadila Pharmaceuticals, Irofulven developed from a
fungus for prostate cancer and APO010 - an immuno-oncology product
for Multiple Myeloma. Oncology Venture has spun out two companies in
Special Purpose Vehicles: 2X Oncology Inc. a US based company
focusing on Precision medicine for women's cancers with a pipeline of
three promising phase 2 product candidates and Danish OV-SPV 2 will
test and potentially develop the Novartis small molecule kinase
inhibitor.

This information is that Oncology Venture Sweden AB is obliged to make
public pursuant to the EU Market Abuse Regulation. The information
was submitted for publication, through the agency of the contact
person set out above, on January 15th 2018.

-----------------------------------------------------------
http://news.cision.com/se/oncology-venture/r/oncology-venture-will-execu...
http://mb.cision.com/Main/12685/2431634/777679.pdf

Författare Aktietorget

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.